Novo Nordisk A/S is on the Cruelty Free Investing use of animals list because they conduct Pre-clinical studies of their drugs on animals to assess a product’s safety profile.
“For a long time to come we will need to use animals for scientific purposes. It is an important goal to ensure that the animals do not suffer unnecessarily, and that is why we have guidelines for how the animals are to be treated – also when they are not being tested, which is 99% of the lifetime of the animals.” Read the following article
Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharmaceuticals segments. The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related products, oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment involves in the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation, and therapy areas. The company was founded by August Krogh, Marie Krogh, Hans Christian Hagedorn, August Kongsted, Harald Pedersen, and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark. [Source: MarketWatch]
Company Website: http://www.novonordisk.com